nodes	percent_of_prediction	percent_of_DWPC	metapath
Trazodone—ORM1—Vemurafenib—melanoma	0.244	0.44	CbGbCtD
Trazodone—ABCB1—melanoma	0.187	1	CbGaD
Trazodone—CYP3A4—Temozolomide—melanoma	0.0588	0.106	CbGbCtD
Trazodone—CYP2D6—Vemurafenib—melanoma	0.0507	0.0913	CbGbCtD
Trazodone—CYP3A7—Docetaxel—melanoma	0.0378	0.0681	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0378	0.0681	CbGbCtD
Trazodone—ABCB1—Dactinomycin—melanoma	0.0357	0.0644	CbGbCtD
Trazodone—CYP3A4—Vemurafenib—melanoma	0.0322	0.058	CbGbCtD
Trazodone—CYP3A5—Docetaxel—melanoma	0.0283	0.0511	CbGbCtD
Trazodone—ABCB1—Docetaxel—melanoma	0.0184	0.0332	CbGbCtD
Trazodone—CYP3A4—Docetaxel—melanoma	0.0111	0.0199	CbGbCtD
Trazodone—Mental disability—Temozolomide—melanoma	0.000805	0.00522	CcSEcCtD
Trazodone—Dysgeusia—Vemurafenib—melanoma	0.000777	0.00504	CcSEcCtD
Trazodone—Eye pain—Carmustine—melanoma	0.000772	0.005	CcSEcCtD
Trazodone—Back pain—Vemurafenib—melanoma	0.000768	0.00498	CcSEcCtD
Trazodone—Lethargy—Dactinomycin—melanoma	0.00076	0.00493	CcSEcCtD
Trazodone—Deafness—Temozolomide—melanoma	0.000753	0.00488	CcSEcCtD
Trazodone—Eye pain—Temozolomide—melanoma	0.000746	0.00484	CcSEcCtD
Trazodone—Amnesia—Carmustine—melanoma	0.000742	0.00481	CcSEcCtD
Trazodone—Nasal congestion—Temozolomide—melanoma	0.000739	0.00479	CcSEcCtD
Trazodone—Amnesia—Temozolomide—melanoma	0.000717	0.00465	CcSEcCtD
Trazodone—Hyponatraemia—Carmustine—melanoma	0.0007	0.00454	CcSEcCtD
Trazodone—Diplopia—Carmustine—melanoma	0.000697	0.00452	CcSEcCtD
Trazodone—Hyperbilirubinaemia—Docetaxel—melanoma	0.000678	0.0044	CcSEcCtD
Trazodone—Myalgia—Vemurafenib—melanoma	0.000676	0.00438	CcSEcCtD
Trazodone—Arthralgia—Vemurafenib—melanoma	0.000676	0.00438	CcSEcCtD
Trazodone—Diplopia—Temozolomide—melanoma	0.000673	0.00437	CcSEcCtD
Trazodone—Ataxia—Carmustine—melanoma	0.000655	0.00425	CcSEcCtD
Trazodone—Hearing impaired—Docetaxel—melanoma	0.000648	0.0042	CcSEcCtD
Trazodone—Ataxia—Temozolomide—melanoma	0.000633	0.00411	CcSEcCtD
Trazodone—Weight decreased—Bleomycin—melanoma	0.000624	0.00405	CcSEcCtD
Trazodone—Acute coronary syndrome—Bleomycin—melanoma	0.000606	0.00393	CcSEcCtD
Trazodone—Hypotension—Vemurafenib—melanoma	0.000605	0.00392	CcSEcCtD
Trazodone—Myocardial infarction—Bleomycin—melanoma	0.000603	0.00391	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00059	0.00383	CcSEcCtD
Trazodone—Haematuria—Bleomycin—melanoma	0.000587	0.0038	CcSEcCtD
Trazodone—Decreased appetite—Vemurafenib—melanoma	0.000563	0.00365	CcSEcCtD
Trazodone—Fatigue—Vemurafenib—melanoma	0.000558	0.00362	CcSEcCtD
Trazodone—Constipation—Vemurafenib—melanoma	0.000554	0.00359	CcSEcCtD
Trazodone—Lightheadedness—Docetaxel—melanoma	0.000552	0.00358	CcSEcCtD
Trazodone—Hypoaesthesia—Bleomycin—melanoma	0.00055	0.00356	CcSEcCtD
Trazodone—Pollakiuria—Temozolomide—melanoma	0.000538	0.00349	CcSEcCtD
Trazodone—Erectile dysfunction—Temozolomide—melanoma	0.000536	0.00348	CcSEcCtD
Trazodone—Photosensitivity reaction—Temozolomide—melanoma	0.000531	0.00344	CcSEcCtD
Trazodone—Weight increased—Temozolomide—melanoma	0.00053	0.00343	CcSEcCtD
Trazodone—Weight decreased—Temozolomide—melanoma	0.000527	0.00341	CcSEcCtD
Trazodone—Flushing—Bleomycin—melanoma	0.000513	0.00332	CcSEcCtD
Trazodone—Body temperature increased—Vemurafenib—melanoma	0.000512	0.00332	CcSEcCtD
Trazodone—Deafness—Docetaxel—melanoma	0.000501	0.00325	CcSEcCtD
Trazodone—Chills—Bleomycin—melanoma	0.000496	0.00321	CcSEcCtD
Trazodone—Cardiac failure congestive—Docetaxel—melanoma	0.000494	0.0032	CcSEcCtD
Trazodone—Alopecia—Bleomycin—melanoma	0.000488	0.00316	CcSEcCtD
Trazodone—Hypoaesthesia—Carmustine—melanoma	0.00048	0.00311	CcSEcCtD
Trazodone—Hallucination—Carmustine—melanoma	0.00048	0.00311	CcSEcCtD
Trazodone—Flushing—Dactinomycin—melanoma	0.000478	0.0031	CcSEcCtD
Trazodone—Hypersensitivity—Vemurafenib—melanoma	0.000477	0.00309	CcSEcCtD
Trazodone—Atrial fibrillation—Docetaxel—melanoma	0.000473	0.00306	CcSEcCtD
Trazodone—Visual disturbance—Docetaxel—melanoma	0.000473	0.00306	CcSEcCtD
Trazodone—Asthenia—Vemurafenib—melanoma	0.000465	0.00301	CcSEcCtD
Trazodone—Visual impairment—Carmustine—melanoma	0.000465	0.00301	CcSEcCtD
Trazodone—Hypoaesthesia—Temozolomide—melanoma	0.000464	0.00301	CcSEcCtD
Trazodone—Hallucination—Temozolomide—melanoma	0.000464	0.00301	CcSEcCtD
Trazodone—Chills—Dactinomycin—melanoma	0.000462	0.003	CcSEcCtD
Trazodone—Pruritus—Vemurafenib—melanoma	0.000458	0.00297	CcSEcCtD
Trazodone—Lethargy—Docetaxel—melanoma	0.000457	0.00296	CcSEcCtD
Trazodone—Alopecia—Dactinomycin—melanoma	0.000455	0.00295	CcSEcCtD
Trazodone—Hyponatraemia—Docetaxel—melanoma	0.00045	0.00292	CcSEcCtD
Trazodone—Visual impairment—Temozolomide—melanoma	0.000449	0.00291	CcSEcCtD
Trazodone—Flushing—Carmustine—melanoma	0.000447	0.0029	CcSEcCtD
Trazodone—Ill-defined disorder—Bleomycin—melanoma	0.000446	0.00289	CcSEcCtD
Trazodone—Anaemia—Bleomycin—melanoma	0.000444	0.00288	CcSEcCtD
Trazodone—Diarrhoea—Vemurafenib—melanoma	0.000443	0.00287	CcSEcCtD
Trazodone—Migraine—Docetaxel—melanoma	0.000441	0.00286	CcSEcCtD
Trazodone—Tinnitus—Temozolomide—melanoma	0.000434	0.00282	CcSEcCtD
Trazodone—Malaise—Bleomycin—melanoma	0.000434	0.00281	CcSEcCtD
Trazodone—Flushing—Temozolomide—melanoma	0.000432	0.0028	CcSEcCtD
Trazodone—Arrhythmia—Carmustine—melanoma	0.000431	0.00279	CcSEcCtD
Trazodone—Dizziness—Vemurafenib—melanoma	0.000428	0.00278	CcSEcCtD
Trazodone—Alopecia—Carmustine—melanoma	0.000426	0.00276	CcSEcCtD
Trazodone—Ataxia—Docetaxel—melanoma	0.000421	0.00273	CcSEcCtD
Trazodone—Chills—Temozolomide—melanoma	0.000418	0.00271	CcSEcCtD
Trazodone—Ill-defined disorder—Dactinomycin—melanoma	0.000416	0.0027	CcSEcCtD
Trazodone—Anaemia—Dactinomycin—melanoma	0.000414	0.00269	CcSEcCtD
Trazodone—Vomiting—Vemurafenib—melanoma	0.000412	0.00267	CcSEcCtD
Trazodone—Alopecia—Temozolomide—melanoma	0.000412	0.00267	CcSEcCtD
Trazodone—Chest pain—Bleomycin—melanoma	0.000409	0.00265	CcSEcCtD
Trazodone—Myalgia—Bleomycin—melanoma	0.000409	0.00265	CcSEcCtD
Trazodone—Orthostatic hypotension—Docetaxel—melanoma	0.000409	0.00265	CcSEcCtD
Trazodone—Rash—Vemurafenib—melanoma	0.000408	0.00265	CcSEcCtD
Trazodone—Dermatitis—Vemurafenib—melanoma	0.000408	0.00265	CcSEcCtD
Trazodone—Back pain—Carmustine—melanoma	0.000406	0.00263	CcSEcCtD
Trazodone—Headache—Vemurafenib—melanoma	0.000406	0.00263	CcSEcCtD
Trazodone—Discomfort—Bleomycin—melanoma	0.000404	0.00262	CcSEcCtD
Trazodone—Malaise—Dactinomycin—melanoma	0.000404	0.00262	CcSEcCtD
Trazodone—Dysgeusia—Temozolomide—melanoma	0.000397	0.00258	CcSEcCtD
Trazodone—Confusional state—Bleomycin—melanoma	0.000396	0.00257	CcSEcCtD
Trazodone—Vision blurred—Carmustine—melanoma	0.000396	0.00256	CcSEcCtD
Trazodone—Tremor—Carmustine—melanoma	0.000393	0.00255	CcSEcCtD
Trazodone—Oedema—Bleomycin—melanoma	0.000392	0.00254	CcSEcCtD
Trazodone—Back pain—Temozolomide—melanoma	0.000392	0.00254	CcSEcCtD
Trazodone—Anaemia—Carmustine—melanoma	0.000388	0.00251	CcSEcCtD
Trazodone—Agitation—Carmustine—melanoma	0.000386	0.0025	CcSEcCtD
Trazodone—Nausea—Vemurafenib—melanoma	0.000385	0.00249	CcSEcCtD
Trazodone—Vision blurred—Temozolomide—melanoma	0.000382	0.00248	CcSEcCtD
Trazodone—Myalgia—Dactinomycin—melanoma	0.000382	0.00248	CcSEcCtD
Trazodone—Tremor—Temozolomide—melanoma	0.00038	0.00246	CcSEcCtD
Trazodone—Discomfort—Dactinomycin—melanoma	0.000377	0.00245	CcSEcCtD
Trazodone—Ill-defined disorder—Temozolomide—melanoma	0.000376	0.00244	CcSEcCtD
Trazodone—Anaemia—Temozolomide—melanoma	0.000375	0.00243	CcSEcCtD
Trazodone—Anorexia—Bleomycin—melanoma	0.000374	0.00243	CcSEcCtD
Trazodone—Agitation—Temozolomide—melanoma	0.000373	0.00242	CcSEcCtD
Trazodone—Hypotension—Bleomycin—melanoma	0.000367	0.00238	CcSEcCtD
Trazodone—Oedema—Dactinomycin—melanoma	0.000366	0.00237	CcSEcCtD
Trazodone—Malaise—Temozolomide—melanoma	0.000366	0.00237	CcSEcCtD
Trazodone—Vertigo—Temozolomide—melanoma	0.000364	0.00236	CcSEcCtD
Trazodone—Hypertension—Carmustine—melanoma	0.000362	0.00235	CcSEcCtD
Trazodone—Palpitations—Temozolomide—melanoma	0.000358	0.00232	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Bleomycin—melanoma	0.000357	0.00232	CcSEcCtD
Trazodone—Chest pain—Carmustine—melanoma	0.000357	0.00232	CcSEcCtD
Trazodone—Myalgia—Carmustine—melanoma	0.000357	0.00232	CcSEcCtD
Trazodone—Anxiety—Carmustine—melanoma	0.000356	0.00231	CcSEcCtD
Trazodone—Paraesthesia—Bleomycin—melanoma	0.000352	0.00228	CcSEcCtD
Trazodone—Weight increased—Docetaxel—melanoma	0.000352	0.00228	CcSEcCtD
Trazodone—Weight decreased—Docetaxel—melanoma	0.00035	0.00227	CcSEcCtD
Trazodone—Hypertension—Temozolomide—melanoma	0.00035	0.00227	CcSEcCtD
Trazodone—Dyspnoea—Bleomycin—melanoma	0.00035	0.00227	CcSEcCtD
Trazodone—Anorexia—Dactinomycin—melanoma	0.000349	0.00226	CcSEcCtD
Trazodone—Confusional state—Carmustine—melanoma	0.000345	0.00224	CcSEcCtD
Trazodone—Arthralgia—Temozolomide—melanoma	0.000345	0.00224	CcSEcCtD
Trazodone—Myalgia—Temozolomide—melanoma	0.000345	0.00224	CcSEcCtD
Trazodone—Anxiety—Temozolomide—melanoma	0.000344	0.00223	CcSEcCtD
Trazodone—Oedema—Carmustine—melanoma	0.000343	0.00222	CcSEcCtD
Trazodone—Discomfort—Temozolomide—melanoma	0.000341	0.00221	CcSEcCtD
Trazodone—Decreased appetite—Bleomycin—melanoma	0.000341	0.00221	CcSEcCtD
Trazodone—Acute coronary syndrome—Docetaxel—melanoma	0.00034	0.00221	CcSEcCtD
Trazodone—Myocardial infarction—Docetaxel—melanoma	0.000338	0.00219	CcSEcCtD
Trazodone—Dry mouth—Temozolomide—melanoma	0.000338	0.00219	CcSEcCtD
Trazodone—Jaundice—Docetaxel—melanoma	0.000336	0.00218	CcSEcCtD
Trazodone—Pain—Bleomycin—melanoma	0.000336	0.00218	CcSEcCtD
Trazodone—Tachycardia—Carmustine—melanoma	0.000334	0.00217	CcSEcCtD
Trazodone—Confusional state—Temozolomide—melanoma	0.000334	0.00216	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000333	0.00216	CcSEcCtD
Trazodone—Oedema—Temozolomide—melanoma	0.000331	0.00215	CcSEcCtD
Trazodone—Anorexia—Carmustine—melanoma	0.000326	0.00212	CcSEcCtD
Trazodone—Feeling abnormal—Bleomycin—melanoma	0.000323	0.0021	CcSEcCtD
Trazodone—Hypotension—Carmustine—melanoma	0.00032	0.00208	CcSEcCtD
Trazodone—Hyperhidrosis—Temozolomide—melanoma	0.00032	0.00207	CcSEcCtD
Trazodone—Decreased appetite—Dactinomycin—melanoma	0.000318	0.00206	CcSEcCtD
Trazodone—Fatigue—Dactinomycin—melanoma	0.000316	0.00205	CcSEcCtD
Trazodone—Anorexia—Temozolomide—melanoma	0.000316	0.00205	CcSEcCtD
Trazodone—Pain—Dactinomycin—melanoma	0.000313	0.00203	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Carmustine—melanoma	0.000312	0.00202	CcSEcCtD
Trazodone—Urticaria—Bleomycin—melanoma	0.000312	0.00202	CcSEcCtD
Trazodone—Body temperature increased—Bleomycin—melanoma	0.00031	0.00201	CcSEcCtD
Trazodone—Insomnia—Carmustine—melanoma	0.00031	0.00201	CcSEcCtD
Trazodone—Hypoaesthesia—Docetaxel—melanoma	0.000308	0.002	CcSEcCtD
Trazodone—Paraesthesia—Carmustine—melanoma	0.000308	0.00199	CcSEcCtD
Trazodone—Dyspnoea—Carmustine—melanoma	0.000305	0.00198	CcSEcCtD
Trazodone—Somnolence—Carmustine—melanoma	0.000304	0.00197	CcSEcCtD
Trazodone—Feeling abnormal—Dactinomycin—melanoma	0.000302	0.00196	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Temozolomide—melanoma	0.000302	0.00196	CcSEcCtD
Trazodone—Insomnia—Temozolomide—melanoma	0.000299	0.00194	CcSEcCtD
Trazodone—Gastrointestinal pain—Dactinomycin—melanoma	0.000299	0.00194	CcSEcCtD
Trazodone—Visual impairment—Docetaxel—melanoma	0.000299	0.00194	CcSEcCtD
Trazodone—Decreased appetite—Carmustine—melanoma	0.000298	0.00193	CcSEcCtD
Trazodone—Paraesthesia—Temozolomide—melanoma	0.000297	0.00193	CcSEcCtD
Trazodone—Dyspnoea—Temozolomide—melanoma	0.000295	0.00191	CcSEcCtD
Trazodone—Somnolence—Temozolomide—melanoma	0.000294	0.00191	CcSEcCtD
Trazodone—Constipation—Carmustine—melanoma	0.000293	0.0019	CcSEcCtD
Trazodone—Pain—Carmustine—melanoma	0.000293	0.0019	CcSEcCtD
Trazodone—Body temperature increased—Dactinomycin—melanoma	0.000289	0.00188	CcSEcCtD
Trazodone—Abdominal pain—Dactinomycin—melanoma	0.000289	0.00188	CcSEcCtD
Trazodone—Hypersensitivity—Bleomycin—melanoma	0.000289	0.00187	CcSEcCtD
Trazodone—Decreased appetite—Temozolomide—melanoma	0.000288	0.00187	CcSEcCtD
Trazodone—Flushing—Docetaxel—melanoma	0.000288	0.00186	CcSEcCtD
Trazodone—Fatigue—Temozolomide—melanoma	0.000285	0.00185	CcSEcCtD
Trazodone—Pain—Temozolomide—melanoma	0.000283	0.00184	CcSEcCtD
Trazodone—Constipation—Temozolomide—melanoma	0.000283	0.00184	CcSEcCtD
Trazodone—Feeling abnormal—Carmustine—melanoma	0.000282	0.00183	CcSEcCtD
Trazodone—Asthenia—Bleomycin—melanoma	0.000282	0.00183	CcSEcCtD
Trazodone—Gastrointestinal pain—Carmustine—melanoma	0.00028	0.00182	CcSEcCtD
Trazodone—Chills—Docetaxel—melanoma	0.000278	0.0018	CcSEcCtD
Trazodone—Pruritus—Bleomycin—melanoma	0.000278	0.0018	CcSEcCtD
Trazodone—Arrhythmia—Docetaxel—melanoma	0.000277	0.00179	CcSEcCtD
Trazodone—Alopecia—Docetaxel—melanoma	0.000274	0.00178	CcSEcCtD
Trazodone—Feeling abnormal—Temozolomide—melanoma	0.000273	0.00177	CcSEcCtD
Trazodone—Abdominal pain—Carmustine—melanoma	0.000271	0.00176	CcSEcCtD
Trazodone—Body temperature increased—Carmustine—melanoma	0.000271	0.00176	CcSEcCtD
Trazodone—Gastrointestinal pain—Temozolomide—melanoma	0.000271	0.00175	CcSEcCtD
Trazodone—Hypersensitivity—Dactinomycin—melanoma	0.00027	0.00175	CcSEcCtD
Trazodone—Dysgeusia—Docetaxel—melanoma	0.000264	0.00171	CcSEcCtD
Trazodone—Urticaria—Temozolomide—melanoma	0.000263	0.0017	CcSEcCtD
Trazodone—Asthenia—Dactinomycin—melanoma	0.000263	0.0017	CcSEcCtD
Trazodone—Body temperature increased—Temozolomide—melanoma	0.000262	0.0017	CcSEcCtD
Trazodone—Abdominal pain—Temozolomide—melanoma	0.000262	0.0017	CcSEcCtD
Trazodone—Back pain—Docetaxel—melanoma	0.000261	0.00169	CcSEcCtD
Trazodone—Hypersensitivity—Carmustine—melanoma	0.000252	0.00164	CcSEcCtD
Trazodone—Diarrhoea—Dactinomycin—melanoma	0.00025	0.00162	CcSEcCtD
Trazodone—Vomiting—Bleomycin—melanoma	0.000249	0.00162	CcSEcCtD
Trazodone—Anaemia—Docetaxel—melanoma	0.000249	0.00162	CcSEcCtD
Trazodone—Rash—Bleomycin—melanoma	0.000247	0.0016	CcSEcCtD
Trazodone—Dermatitis—Bleomycin—melanoma	0.000247	0.0016	CcSEcCtD
Trazodone—Asthenia—Carmustine—melanoma	0.000246	0.00159	CcSEcCtD
Trazodone—Hypersensitivity—Temozolomide—melanoma	0.000244	0.00158	CcSEcCtD
Trazodone—Syncope—Docetaxel—melanoma	0.000242	0.00157	CcSEcCtD
Trazodone—Palpitations—Docetaxel—melanoma	0.000238	0.00155	CcSEcCtD
Trazodone—Asthenia—Temozolomide—melanoma	0.000237	0.00154	CcSEcCtD
Trazodone—Loss of consciousness—Docetaxel—melanoma	0.000237	0.00154	CcSEcCtD
Trazodone—Diarrhoea—Carmustine—melanoma	0.000234	0.00152	CcSEcCtD
Trazodone—Pruritus—Temozolomide—melanoma	0.000234	0.00152	CcSEcCtD
Trazodone—Nausea—Bleomycin—melanoma	0.000233	0.00151	CcSEcCtD
Trazodone—Hypertension—Docetaxel—melanoma	0.000233	0.00151	CcSEcCtD
Trazodone—Vomiting—Dactinomycin—melanoma	0.000233	0.00151	CcSEcCtD
Trazodone—Rash—Dactinomycin—melanoma	0.000231	0.0015	CcSEcCtD
Trazodone—Arthralgia—Docetaxel—melanoma	0.00023	0.00149	CcSEcCtD
Trazodone—Chest pain—Docetaxel—melanoma	0.00023	0.00149	CcSEcCtD
Trazodone—Myalgia—Docetaxel—melanoma	0.00023	0.00149	CcSEcCtD
Trazodone—Dizziness—Carmustine—melanoma	0.000226	0.00147	CcSEcCtD
Trazodone—Diarrhoea—Temozolomide—melanoma	0.000226	0.00147	CcSEcCtD
Trazodone—Dry mouth—Docetaxel—melanoma	0.000225	0.00146	CcSEcCtD
Trazodone—Confusional state—Docetaxel—melanoma	0.000222	0.00144	CcSEcCtD
Trazodone—Oedema—Docetaxel—melanoma	0.00022	0.00143	CcSEcCtD
Trazodone—Dizziness—Temozolomide—melanoma	0.000219	0.00142	CcSEcCtD
Trazodone—Vomiting—Carmustine—melanoma	0.000218	0.00141	CcSEcCtD
Trazodone—Nausea—Dactinomycin—melanoma	0.000217	0.00141	CcSEcCtD
Trazodone—Shock—Docetaxel—melanoma	0.000217	0.0014	CcSEcCtD
Trazodone—Rash—Carmustine—melanoma	0.000216	0.0014	CcSEcCtD
Trazodone—Dermatitis—Carmustine—melanoma	0.000216	0.0014	CcSEcCtD
Trazodone—Tachycardia—Docetaxel—melanoma	0.000215	0.00139	CcSEcCtD
Trazodone—Headache—Carmustine—melanoma	0.000215	0.00139	CcSEcCtD
Trazodone—Vomiting—Temozolomide—melanoma	0.00021	0.00136	CcSEcCtD
Trazodone—Anorexia—Docetaxel—melanoma	0.00021	0.00136	CcSEcCtD
Trazodone—Rash—Temozolomide—melanoma	0.000209	0.00135	CcSEcCtD
Trazodone—Dermatitis—Temozolomide—melanoma	0.000208	0.00135	CcSEcCtD
Trazodone—Headache—Temozolomide—melanoma	0.000207	0.00134	CcSEcCtD
Trazodone—Hypotension—Docetaxel—melanoma	0.000206	0.00133	CcSEcCtD
Trazodone—Nausea—Carmustine—melanoma	0.000203	0.00132	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000201	0.0013	CcSEcCtD
Trazodone—Insomnia—Docetaxel—melanoma	0.000199	0.00129	CcSEcCtD
Trazodone—Paraesthesia—Docetaxel—melanoma	0.000198	0.00128	CcSEcCtD
Trazodone—Nausea—Temozolomide—melanoma	0.000197	0.00127	CcSEcCtD
Trazodone—Dyspnoea—Docetaxel—melanoma	0.000196	0.00127	CcSEcCtD
Trazodone—Somnolence—Docetaxel—melanoma	0.000196	0.00127	CcSEcCtD
Trazodone—Decreased appetite—Docetaxel—melanoma	0.000191	0.00124	CcSEcCtD
Trazodone—Fatigue—Docetaxel—melanoma	0.00019	0.00123	CcSEcCtD
Trazodone—Pain—Docetaxel—melanoma	0.000188	0.00122	CcSEcCtD
Trazodone—Constipation—Docetaxel—melanoma	0.000188	0.00122	CcSEcCtD
Trazodone—Feeling abnormal—Docetaxel—melanoma	0.000181	0.00118	CcSEcCtD
Trazodone—Gastrointestinal pain—Docetaxel—melanoma	0.00018	0.00117	CcSEcCtD
Trazodone—Body temperature increased—Docetaxel—melanoma	0.000174	0.00113	CcSEcCtD
Trazodone—Abdominal pain—Docetaxel—melanoma	0.000174	0.00113	CcSEcCtD
Trazodone—Hypersensitivity—Docetaxel—melanoma	0.000162	0.00105	CcSEcCtD
Trazodone—Asthenia—Docetaxel—melanoma	0.000158	0.00102	CcSEcCtD
Trazodone—Pruritus—Docetaxel—melanoma	0.000156	0.00101	CcSEcCtD
Trazodone—Diarrhoea—Docetaxel—melanoma	0.000151	0.000976	CcSEcCtD
Trazodone—Clozapine—CYP1B1—melanoma	0.000147	0.212	CrCbGaD
Trazodone—Dizziness—Docetaxel—melanoma	0.000146	0.000944	CcSEcCtD
Trazodone—Vomiting—Docetaxel—melanoma	0.00014	0.000907	CcSEcCtD
Trazodone—Rash—Docetaxel—melanoma	0.000139	0.0009	CcSEcCtD
Trazodone—Dermatitis—Docetaxel—melanoma	0.000139	0.000899	CcSEcCtD
Trazodone—Headache—Docetaxel—melanoma	0.000138	0.000894	CcSEcCtD
Trazodone—Nausea—Docetaxel—melanoma	0.000131	0.000848	CcSEcCtD
Trazodone—Domperidone—ABCB1—melanoma	0.000102	0.146	CrCbGaD
Trazodone—Nefazodone—ABCB1—melanoma	8.44e-05	0.122	CrCbGaD
Trazodone—Aripiprazole—ABCB1—melanoma	7.85e-05	0.113	CrCbGaD
Trazodone—Thioproperazine—ALB—melanoma	7.8e-05	0.112	CrCbGaD
Trazodone—Fluphenazine—ABCB1—melanoma	6.33e-05	0.0911	CrCbGaD
Trazodone—Trifluoperazine—ABCB1—melanoma	5.06e-05	0.0728	CrCbGaD
Trazodone—Quetiapine—ABCB1—melanoma	4.91e-05	0.0706	CrCbGaD
Trazodone—Clozapine—ABCB1—melanoma	4.22e-05	0.0608	CrCbGaD
Trazodone—HTR2B—Signaling Pathways—VEGFA—melanoma	5.72e-06	5.56e-05	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	5.71e-06	5.55e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CXCL8—melanoma	5.71e-06	5.55e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CXCL8—melanoma	5.68e-06	5.52e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—HRAS—melanoma	5.68e-06	5.51e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—STAT3—melanoma	5.67e-06	5.5e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—SLC5A5—melanoma	5.65e-06	5.49e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—NRAS—melanoma	5.65e-06	5.49e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—KRAS—melanoma	5.65e-06	5.49e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—HRAS—melanoma	5.65e-06	5.48e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—FGF2—melanoma	5.64e-06	5.48e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—FGF2—melanoma	5.63e-06	5.47e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CB—melanoma	5.59e-06	5.43e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IGF1—melanoma	5.58e-06	5.42e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CDKN1B—melanoma	5.58e-06	5.42e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—MAPK1—melanoma	5.56e-06	5.4e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—EGFR—melanoma	5.56e-06	5.4e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CDKN1B—melanoma	5.55e-06	5.39e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTGS2—melanoma	5.54e-06	5.38e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—FGF2—melanoma	5.52e-06	5.37e-05	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—AKT1—melanoma	5.52e-06	5.36e-05	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—AKT1—melanoma	5.49e-06	5.33e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CASP3—melanoma	5.47e-06	5.31e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IL2—melanoma	5.46e-06	5.3e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CD44—melanoma	5.46e-06	5.3e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GNAQ—melanoma	5.46e-06	5.3e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CASP3—melanoma	5.44e-06	5.28e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—IL6—melanoma	5.43e-06	5.28e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IL2—melanoma	5.43e-06	5.28e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MAPK3—melanoma	5.41e-06	5.26e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—IL6—melanoma	5.4e-06	5.25e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MAP2K1—melanoma	5.4e-06	5.24e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CD—melanoma	5.36e-06	5.21e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CCND1—melanoma	5.32e-06	5.17e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	5.31e-06	5.16e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—PIK3CA—melanoma	5.3e-06	5.15e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CCND1—melanoma	5.3e-06	5.14e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—PIK3CA—melanoma	5.29e-06	5.14e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MDM2—melanoma	5.28e-06	5.13e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CTNNB1—melanoma	5.27e-06	5.12e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MDM2—melanoma	5.27e-06	5.12e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MYC—melanoma	5.26e-06	5.11e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—KRAS—melanoma	5.25e-06	5.1e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CTNNB1—melanoma	5.24e-06	5.09e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CYP1B1—melanoma	5.23e-06	5.08e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—ERBB2—melanoma	5.2e-06	5.06e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—ERBB2—melanoma	5.19e-06	5.04e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	5.19e-06	5.04e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MDM2—melanoma	5.17e-06	5.02e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MMP9—melanoma	5.17e-06	5.02e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MAPK1—melanoma	5.15e-06	5e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—EGFR—melanoma	5.15e-06	5e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CDKN1A—melanoma	5.15e-06	5e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MMP9—melanoma	5.14e-06	4.99e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PTEN—melanoma	5.14e-06	4.99e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CB—melanoma	5.14e-06	4.99e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—FGF2—melanoma	5.13e-06	4.99e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CB—melanoma	5.12e-06	4.98e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CDKN1A—melanoma	5.12e-06	4.98e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CB—melanoma	5.12e-06	4.97e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—NFKB1—melanoma	5.11e-06	4.97e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PTEN—melanoma	5.11e-06	4.96e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—ERBB2—melanoma	5.1e-06	4.95e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—NFKB1—melanoma	5.09e-06	4.94e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTGS2—melanoma	5.07e-06	4.93e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CG—melanoma	5.04e-06	4.9e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CB—melanoma	5.03e-06	4.88e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—AKT1—melanoma	5.01e-06	4.87e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—AKT1—melanoma	4.99e-06	4.84e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CXCL8—melanoma	4.94e-06	4.79e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CXCL8—melanoma	4.92e-06	4.78e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—HRAS—melanoma	4.9e-06	4.76e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—HRAS—melanoma	4.89e-06	4.75e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARG—melanoma	4.87e-06	4.73e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—KRAS—melanoma	4.86e-06	4.72e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CXCL8—melanoma	4.83e-06	4.69e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTEN—melanoma	4.83e-06	4.69e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	4.82e-06	4.68e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CDKN1B—melanoma	4.82e-06	4.68e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CDKN1B—melanoma	4.81e-06	4.67e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MDM2—melanoma	4.8e-06	4.66e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—HRAS—melanoma	4.8e-06	4.66e-05	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—AKT1—melanoma	4.77e-06	4.63e-05	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—AKT1—melanoma	4.76e-06	4.62e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CG—melanoma	4.75e-06	4.62e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—ERBB2—melanoma	4.73e-06	4.6e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CASP3—melanoma	4.72e-06	4.59e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CDKN1B—melanoma	4.72e-06	4.58e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IL2—melanoma	4.72e-06	4.58e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CASP3—melanoma	4.71e-06	4.58e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IL2—melanoma	4.71e-06	4.57e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—IL6—melanoma	4.69e-06	4.56e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—IL6—melanoma	4.68e-06	4.55e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CB—melanoma	4.67e-06	4.54e-05	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—AKT1—melanoma	4.67e-06	4.53e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—VEGFA—melanoma	4.64e-06	4.51e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CASP3—melanoma	4.63e-06	4.49e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IL2—melanoma	4.62e-06	4.49e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—VEGFA—melanoma	4.62e-06	4.48e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CCND1—melanoma	4.6e-06	4.47e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—IL6—melanoma	4.6e-06	4.46e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—STAT3—melanoma	4.59e-06	4.46e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CCND1—melanoma	4.59e-06	4.46e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARG—melanoma	4.59e-06	4.45e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—NRAS—melanoma	4.58e-06	4.45e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—STAT3—melanoma	4.57e-06	4.44e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—NRAS—melanoma	4.56e-06	4.43e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CTNNB1—melanoma	4.55e-06	4.42e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CTNNB1—melanoma	4.54e-06	4.41e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CCND1—melanoma	4.5e-06	4.37e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CXCL8—melanoma	4.49e-06	4.36e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—PIK3CA—melanoma	4.47e-06	4.34e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MMP9—melanoma	4.46e-06	4.34e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—HRAS—melanoma	4.46e-06	4.33e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CTNNB1—melanoma	4.46e-06	4.33e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MMP9—melanoma	4.45e-06	4.33e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CDKN1A—melanoma	4.45e-06	4.32e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CDKN1A—melanoma	4.44e-06	4.31e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PTEN—melanoma	4.44e-06	4.31e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CD—melanoma	4.43e-06	4.31e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PTEN—melanoma	4.43e-06	4.3e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTEN—melanoma	4.42e-06	4.3e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NFKB1—melanoma	4.42e-06	4.29e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NFKB1—melanoma	4.41e-06	4.28e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MAPK3—melanoma	4.39e-06	4.26e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CDKN1B—melanoma	4.39e-06	4.26e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—ALB—melanoma	4.38e-06	4.25e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MMP9—melanoma	4.37e-06	4.25e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MAPK3—melanoma	4.37e-06	4.24e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CDKN1A—melanoma	4.36e-06	4.23e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PTEN—melanoma	4.35e-06	4.22e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—AKT1—melanoma	4.34e-06	4.21e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—AKT1—melanoma	4.33e-06	4.21e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NFKB1—melanoma	4.32e-06	4.2e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TP53—melanoma	4.32e-06	4.2e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—AKT1—melanoma	4.32e-06	4.2e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PIK3CA—melanoma	4.32e-06	4.19e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ABCB1—melanoma	4.31e-06	4.19e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CASP3—melanoma	4.3e-06	4.17e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IL2—melanoma	4.29e-06	4.17e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—IL6—melanoma	4.27e-06	4.15e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MYC—melanoma	4.27e-06	4.15e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MYC—melanoma	4.25e-06	4.13e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—AKT1—melanoma	4.24e-06	4.12e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CCND1—melanoma	4.18e-06	4.06e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CD—melanoma	4.18e-06	4.06e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MAPK1—melanoma	4.18e-06	4.06e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—EGFR—melanoma	4.18e-06	4.06e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MAPK1—melanoma	4.15e-06	4.04e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—EGFR—melanoma	4.15e-06	4.03e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CTNNB1—melanoma	4.14e-06	4.02e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—HRAS—melanoma	4.13e-06	4.02e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—ALB—melanoma	4.12e-06	4.01e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MMP9—melanoma	4.06e-06	3.94e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CDKN1A—melanoma	4.05e-06	3.93e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PTEN—melanoma	4.04e-06	3.92e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NFKB1—melanoma	4.02e-06	3.9e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—VEGFA—melanoma	4.01e-06	3.89e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—VEGFA—melanoma	4e-06	3.89e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—STAT3—melanoma	3.97e-06	3.86e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PRKCA—melanoma	3.97e-06	3.85e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—STAT3—melanoma	3.96e-06	3.85e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NRAS—melanoma	3.96e-06	3.85e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—IL6—melanoma	3.96e-06	3.84e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NRAS—melanoma	3.95e-06	3.84e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—KRAS—melanoma	3.94e-06	3.83e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.94e-06	3.83e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ERCC2—melanoma	3.93e-06	3.82e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.93e-06	3.81e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—KRAS—melanoma	3.92e-06	3.81e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—STAT3—melanoma	3.89e-06	3.77e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NRAS—melanoma	3.88e-06	3.77e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CB—melanoma	3.86e-06	3.75e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTGS2—melanoma	3.83e-06	3.72e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MAPK3—melanoma	3.79e-06	3.68e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MAPK3—melanoma	3.78e-06	3.68e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.71e-06	3.61e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MYC—melanoma	3.69e-06	3.58e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MYC—melanoma	3.68e-06	3.57e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—AKT1—melanoma	3.65e-06	3.55e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—VEGFA—melanoma	3.65e-06	3.54e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CB—melanoma	3.64e-06	3.54e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PIK3CA—melanoma	3.62e-06	3.52e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MYC—melanoma	3.61e-06	3.51e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—STAT3—melanoma	3.61e-06	3.51e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MAPK1—melanoma	3.61e-06	3.5e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTGS2—melanoma	3.61e-06	3.5e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—EGFR—melanoma	3.61e-06	3.5e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PIK3CA—melanoma	3.61e-06	3.5e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NRAS—melanoma	3.6e-06	3.5e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MAPK1—melanoma	3.6e-06	3.5e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—EGFR—melanoma	3.6e-06	3.5e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.53e-06	3.43e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—EGFR—melanoma	3.53e-06	3.43e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—AKT1—melanoma	3.53e-06	3.43e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TP53—melanoma	3.51e-06	3.41e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TP53—melanoma	3.49e-06	3.39e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MAPK3—melanoma	3.45e-06	3.35e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—KRAS—melanoma	3.41e-06	3.31e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CA—melanoma	3.41e-06	3.31e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—KRAS—melanoma	3.4e-06	3.3e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MYC—melanoma	3.36e-06	3.26e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—HRAS—melanoma	3.35e-06	3.26e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTEN—melanoma	3.34e-06	3.24e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—KRAS—melanoma	3.34e-06	3.24e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—HRAS—melanoma	3.34e-06	3.24e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MAPK1—melanoma	3.28e-06	3.19e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—EGFR—melanoma	3.28e-06	3.19e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IL6—melanoma	3.21e-06	3.12e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IL6—melanoma	3.19e-06	3.1e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTEN—melanoma	3.15e-06	3.06e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CA—melanoma	3.13e-06	3.04e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CA—melanoma	3.12e-06	3.03e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CA—melanoma	3.12e-06	3.03e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CG—melanoma	3.11e-06	3.02e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—KRAS—melanoma	3.1e-06	3.01e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CA—melanoma	3.07e-06	2.98e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TP53—melanoma	3.03e-06	2.94e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TP53—melanoma	3.02e-06	2.94e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARG—melanoma	3e-06	2.91e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TP53—melanoma	2.97e-06	2.88e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—AKT1—melanoma	2.96e-06	2.88e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—AKT1—melanoma	2.95e-06	2.86e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—HRAS—melanoma	2.9e-06	2.81e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—HRAS—melanoma	2.89e-06	2.81e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.85e-06	2.77e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—HRAS—melanoma	2.84e-06	2.75e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—AKT1—melanoma	2.78e-06	2.7e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IL6—melanoma	2.77e-06	2.69e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IL6—melanoma	2.77e-06	2.69e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TP53—melanoma	2.76e-06	2.68e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CD—melanoma	2.73e-06	2.65e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IL6—melanoma	2.71e-06	2.64e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ALB—melanoma	2.7e-06	2.62e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—HRAS—melanoma	2.64e-06	2.56e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—AKT1—melanoma	2.56e-06	2.48e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—AKT1—melanoma	2.55e-06	2.48e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—AKT1—melanoma	2.55e-06	2.48e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IL6—melanoma	2.52e-06	2.45e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—AKT1—melanoma	2.5e-06	2.43e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CB—melanoma	2.38e-06	2.31e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTGS2—melanoma	2.36e-06	2.29e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CA—melanoma	2.36e-06	2.29e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—AKT1—melanoma	2.33e-06	2.26e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CA—melanoma	2.22e-06	2.16e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTEN—melanoma	2.06e-06	2e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—AKT1—melanoma	1.92e-06	1.87e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—AKT1—melanoma	1.81e-06	1.76e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CA—melanoma	1.45e-06	1.41e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—AKT1—melanoma	1.19e-06	1.15e-05	CbGpPWpGaD
